Tesamorelin and GHK-Cu on TikTok: separating hype from data

What did @jojonicole93 actually say?

She said she just finished a "reticycle" and is starting a new cycle combining GHK-Cu and what she calls "Tessa Morellon" (tesamorelin). Her stated goal is to "target this visceral fat belly pooch" and "get toned." That is the entirety of the clinical claim here. No dosing mentioned, no protocol specifics, just a before-style reveal and a goal.

To be fair to the creator, she kept it brief. She did not claim these peptides cure anything or guarantee results. What she did do is imply that this specific stack will produce body composition changes, particularly visceral fat reduction, which is a more specific claim than it might sound on the surface. The science on each compound is different enough that treating them as a unified "fat loss stack" deserves scrutiny.

Does the science back this up?

For tesamorelin, yes, there is actual clinical evidence. For GHK-Cu as a visceral fat treatment, essentially none exists in humans.

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone. The approval (brand name Egrifta) is specifically for HIV-associated lipodystrophy, meaning excess visceral fat in HIV-positive patients on antiretroviral therapy. The pivotal trials, including Falutz et al. (2010, New England Journal of Medicine), showed statistically significant reductions in visceral adipose tissue measured by CT scan. That is real, peer-reviewed evidence of visceral fat reduction. However, those results were in a specific patient population with a specific metabolic condition, not in generally healthy people trying to reduce a "belly pooch."

GHK-Cu is a copper peptide with reasonably well-studied wound healing and skin regeneration properties in vitro. Pickart et al. (2012, Journal of Biomaterials Science) documented its role in collagen synthesis and tissue repair. As a visceral fat intervention? There is no credible human trial data supporting that use. Stacking it with tesamorelin for fat loss is not a studied combination.

What did they get wrong (or right)?

She gets partial credit on tesamorelin. The drug does have documented visceral fat reduction effects, so the directional claim is not invented. But the application is off. Tesamorelin's evidence base is almost entirely in HIV-associated lipodystrophy. Using it off-label for general body composition goals is a different situation, and assuming the same outcomes apply to a metabolically healthy person is a significant leap that the literature does not support cleanly.

On GHK-Cu as a fat-targeting agent, she is on much shakier ground. The compound has legitimate research behind it for skin and tissue applications. Describing it as part of a visceral fat cycle implies a mechanism and an outcome that has not been demonstrated in any published human trial. That is misleading by implication, even if she never said the words "GHK-Cu burns fat."

The framing of a "cycle" also carries real risk. Both compounds, particularly tesamorelin, affect the growth hormone axis. Cycling growth hormone secretagogues without medical supervision and monitoring of IGF-1 levels is not a trivial thing. She did not recommend anyone else do this, which is worth noting, but the aspirational framing normalizes unsupervised peptide stacking for a young audience.

What should you actually know?

Tesamorelin is a real pharmaceutical with a real approval and real evidence behind it in a specific context. That context matters enormously. The FDA approved it for a defined condition, not for general cosmetic fat reduction. Compounded versions available through telehealth platforms are not equivalent to the brand-name drug, and their purity and dosing consistency are not guaranteed by the same standards.

GHK-Cu is interesting science at the cellular level. Researchers have looked at it for wound healing, anti-inflammatory effects, and skin remodeling. Using it as part of a fat loss stack is extrapolating well beyond what the evidence supports. Anyone claiming GHK-Cu will help "target" visceral fat is selling a story the data has not written yet.

If you are considering tesamorelin for off-label body composition goals, that conversation needs to happen with a licensed provider who can order baseline and follow-up IGF-1 testing, review your metabolic history, and actually monitor what the drug is doing to your growth hormone axis. A TikTok cycle reveal is not a protocol.